ArticleNature chemistry2026
Concise synthesis and strain-release diversification of bridgehead-substituted [2]-ladderanes.
Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ladder-shaped molecules for the masses.Nature chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Strained hydrocarbons offer privileged platforms for accessing otherwise elusive reactivity and molecular architectures. Among these, [2]-ladderane scaffolds hold considerable promise, yet modular access to diversely functionalized derivatives remains a major challenge. Here we report a concise and scalable strategy for the efficient synthesis of bridgehead-substituted [2]-ladderanes from readily available precursors. The resulting ladderanes serve as versatile intermediates for programmable, regioselective bridgehead functionalization and strain-release cycloadditions with electron-deficient alkenes, granting access to a broad array of multisubstituted bicyclo[2.2.2]octanes (BCOs). Furthermore, BCO scaffolds were leveraged for site-selective diversification and as saturated isosteres for benzene rings in pharmaceutically relevant molecules, leading to enhanced three-dimensionality and tunable physicochemical properties. Collectively, this work overcomes long-standing synthetic limitations and establishes bridgehead-substituted [2]-ladderanes and BCOs as modular platforms for complex molecule construction and rational molecular design.
Identifiers
42363021What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.